



CYTOMEDIX TO PRESENT AT GROWTH STOCK CONFERENCE HOSTED BY SECURITY RESEARCH ASSOCIATES, INC.

ROCKVILLE, Md. (October 15, 2009) – Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Martin Rosendale, Chief Executive Officer of Cytomedix, will be presenting a corporate update at Security Research Associates' Growth Stock Conference on Monday, October 19th at 4:00 p.m. (Eastern Time) at the Omni Hotel in New York, New York.

Conference attendees will include a select group of institutional portfolio managers and analysts, and will feature CEOs and CFOs from some of the fastest growing companies in the micro and small cap spaces. SRA has arranged for webcasting of company presentations during this event. To access the lobby page for the webcast of presenting companies, including Cytomedix, Inc., please go to: <http://www.wsw.com/webcast/sra9/>

About Security Research Associates, Inc.

Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA visit their web site at www.sracap.com or call them at 415-925-0346.

About Cytomedix

Cytomedix develops, sells and licenses regenerative biological therapies including the AutoloGel™ System, a device for the production of Platelet Rich Plasma ("PRP") gel derived from the patient's own blood. The AutoloGel™ System is cleared by the U.S. Food and Drug Administration for use on a variety of exuding wounds. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel™ System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing

strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, its ability to successfully commercialize its product in Japan under the terms of the license agreement, and Cytomedix's ability to execute on its strategy to market the AutoloGel(tm) System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Contacts:

Cytomedix, Inc.

David Jorden, Executive Board Member
Martin Rosendale, CEO
(240) 499-2680

Lippert/Heilshorn & Associates

Anne Marie Fields
(afields@lhai.com)
(212) 838-3777

#